$CYNO (Cynosure, Inc.)

$CYNO {{ '2016-07-26T17:07:03+0000' | timeago}} • Announcement

$CYNO said it got approval from Korean Ministry of Food and Drug Safety (MFDS) to market SculpSure for non-invasive lipolysis of abdomen and flanks. The product will be marketed through its direct sales force in Korea beginning in 3Q16. SculpSure is effective non-invasive treatment that eliminates up to 24% of treated fat in 25-minute procedure.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$HOLX {{ '2018-01-16T13:05:50+0000' | timeago}} • Announcement

$HOLX said its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for in vitro diagnostic. The Aptima HIV-1 Quant Dx assay is the first HIV-1 viral load assay with a dual claim for both diagnosis and treatment monitoring.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CUTR {{ '2018-01-08T18:33:07+0000' | timeago}} • Announcement

$CUTR introduced Juliet and Secret RF to its product offerings of laser and energy-based devices. The Juliet laser is intended for treatment in the area of women’s health. Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves mild wrinkles, and diminishes scars.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$BABY {{ '2018-01-08T12:48:13+0000' | timeago}} • Announcement

$BABY said that for FY18, the company expects revenue of $535-540MM and non-GAAP EPS of $1.60-1.65. For 1Q18, the company expects revenue of $125-127MM and non-GAAP EPS of $0.23-0.24. For 4Q17, $BABY expects to report revenue of approx. $131-132MM, while for FY17 revenue is expected to be $500.5-501.5MM.

$BABY {{ '2018-01-05T14:35:34+0000' | timeago}} • Announcement

$BABY appointed Leslie McDonnell as VP and General Manager of its Newborn Care Business Unit. McDonnell will report to CEO Jim Hawkins, and will be responsible for leading and expanding Natus' newborn care business. McDonnell is expected to join Natus on Feb. 12, 2018.

$BABY {{ '2018-01-05T14:07:05+0000' | timeago}} • Announcement

$BABY has named Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit. Ms. McDonnell will report to Jim Hawkins, CEO. She is expected to join $BABY on February 12, 2018.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
ELMD (Electromed, Inc.)
Wednesday, November 8 2017 - 2:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
CUTR (Cutera, Inc.)
Tuesday, November 7 2017 - 9:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BABY (Natus Medical Inc.)
Wednesday, October 25 2017 - 3:00pm
PHG (Koninklijke Philips N.V)
Monday, October 23 2017 - 8:00am
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
ELMD (Electromed, Inc.)
Wednesday, September 6 2017 - 1:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like